This inventor holds 2 USPTO granted patents, plus 2 CIPO patents and 2 EPO patents. Top assignees: Abclon Inc., Yuhan Corporation. Active years: 2019-2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2019-2022
Title: Bong-Kook Ko: Innovator in Cancer Treatment
Introduction
Bong-Kook Ko is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of cancer treatment through his innovative research and development of novel antibodies. With a total of 2 patents, his work focuses on targeting specific proteins involved in tumor immunosuppression and cancer cell proliferation.
Latest Patents
Bong-Kook Ko's latest patents include groundbreaking inventions such as anti-TIGIT antibodies and antibodies specifically binding to HER2. The anti-TIGIT antibodies are designed to bind to the tumor-immunosuppressant TIGIT, providing a potential therapeutic avenue for cancer treatment. This invention encompasses a novel antibody, a nucleic acid encoding the antibody, and a pharmaceutical composition that can be used to treat cancer or tumors.
The second patent involves antibodies that specifically target HER2, a protein over-expressed in certain cancer cells, particularly breast and stomach cancers. These antibodies are unique in their CDR sequences, which exhibit low similarity to existing HER2 antibodies. The combination of these antibodies with trastuzumab has shown significantly enhanced cytotoxicity against cancer cells, making them a promising option for cancer therapy.
Career Highlights
Throughout his career, Bong-Kook Ko has worked with notable companies such as Yuhan Corporation and Abclon Inc. His experience in these organizations has contributed to his expertise in developing innovative therapeutic solutions for cancer treatment.
Collaborations
Bong-Kook Ko has collaborated with esteemed colleagues, including Kyu-Tae Kim and Jong-Seo Lee. These partnerships have fostered a collaborative environment that enhances the research and development of effective cancer therapies.
Conclusion
Bong-Kook Ko is a distinguished inventor whose work in developing innovative antibodies has the potential to transform cancer treatment. His contributions to the field are marked by his unique patents and collaborations with other experts. The advancements he has made in targeting specific proteins involved in cancer progression highlight his commitment to improving therapeutic options for patients.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile